Increasing the dosage of vincristine: A clinical and pharmacokinetic study of continuous-infusion vincristine in children with central nervous system tumors

Cancer

Volumn 100, Issue 12, 2004, Pages 2637-2643

  Kellie, Stewart J ^a,b   Koopmans, Pauline ^c   Earl, John ^a   Nath, Christa ^a   Roebuck, Derek ^a   Uges, Donald R A ^c   De Graaf, Siebold S N ^d,e  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d UNIVERSITY OF GRONINGEN   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Brain tumors; Chemotherapy neurotoxicity; Children; Infusion; Pharmacokinetics; Vincristine

Indexed keywords

CYCLOPHOSPHAMIDE; VASOPRESSIN; VINCRISTINE;

ABDOMINAL PAIN; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTROCYTOMA; BOLUS INJECTION; BONE MARROW SUPPRESSION; BRAIN DISEASE; BRAIN TUMOR; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CHILDHOOD CANCER; CHOROID PLEXUS TUMOR; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COMA; CONCENTRATION RESPONSE; CONSTIPATION; CONTINUOUS INFUSION; CRANIAL NERVE PARALYSIS; CYTOTOXICITY; DEPRESSION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG MEGADOSE; DYSPHAGIA; EPENDYMOMA; FACIAL NERVE PARALYSIS; FEMALE; GLIOMA; HALLUCINATION; HEARING LOSS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOARSENESS; HUMAN; ILEUS; IN VITRO STUDY; IN VIVO STUDY; INAPPROPRIATE VASOPRESSIN SECRETION; INSOMNIA; JAW PAIN; MALE; MEDULLOBLASTOMA; NEUROECTODERM TUMOR; NEUROPATHY; NEUROTOXICITY; OPHTHALMOPLEGIA; PAIN; PONS; PRIORITY JOURNAL; PTOSIS; REFLEX DISORDER; SEIZURE; STEADY STATE;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; MALE; TREATMENT OUTCOME; VINCRISTINE;

EID: 2642520380     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20220     Document Type: Article

References (42)

1. Gidding CE, Kellie SJ, Kamps WA, de Graaf SS. Vincristine revisited. Crit Rev Oncol Hematol. 1999;29:267-287.
2. Frei E III, Canellos GP. Dose: a critical factor in cancer chemotherapy. Am J Med. 1980;69:585-594.
3. Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med. 1981; 304:10-15.
4. Crom WR, de Graaf SS, Synold T, et al. Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia. J Pediatr. 1994;125:642-649.
5. de Graaf SS, Bloemhof H, Vendrig DE, Uges DR. Vincristine disposition in children with acute lymphoblastic leukemia. Med Pediatr Oncol. 1995;24:235-240.
6. Houghton JA, Meyer WH, Houghton PJ. Scheduling of vincristine: drug accumulation and response of xenografts of childhood rhabdomyosarcoma determined by frequency of administration. Cancer Treat Rep. 1987;71:717-721.
7. Himes RH, Kersey RN, Heller-Bettinger I, Samson FE. Action of the vinca alkaloids vincristine, vinblastine, and desacetyl vinblastine amide on microtubules in vitro. Cancer Res. 1976;36:3798-3802.
8. Owellen RJ, Hartke CA, Dickerson RM, Hains FO. Inhibition of tubulin-microtubule polymerization by drugs of the vinca alkaloid class. Cancer Res. 1976;36:1499-1502.
9. Rosenstock JG, Evans AE, Schut L. Response to vincristine of recurrent brain tumors in children. J Neurosurg. 1976;45: 135-140.
10. Smart CR, Ottoman RE, Rochlin DB, et al. Clinical experience with vincristine (NSC-67574) in tumors of the central nervous system and other malignant diseases. Cancer Chemother Rep. 1968;52:733-741.
11. Lampkin BC, Mauer AM, McBride BH. Response of medulloblastoma to vincristine sulphate: a case report. Pediatrics. 1967;39:761-763.
12. Lassman LP, Pearce GW, Banna M, Jones RD. Vincristine sulphate in the treatment of skeletal metastases from cerebellar medulloblastoma. J Neurosurg. 1969;30:42-49.
13. Lassman LP, Pearce GW, Gang J. Effect of vincristine sulphate on the intracranial gliomata of childhood. Br J Surg. 1966;53:774-777.
14. Allen JC, Helson L. High-dose cyclophosphamide chemotherapy for recurrent CNS tumors in children. J Neurosurg. 1981;55:749-756.
15. Allen JC, Helson L, Jereb B. Preradiation chemotherapy for newly diagnosed childhood brain tumors. A modified Phase II trial. Cancer. 1983;52:2001-2006.
16. Gajjar A, Heideman RL, Kovnar EH, et al. Response of pediatric low grade gliomas to chemotherapy. Pediatr Neurosurg. 1993;19:113-120.
17. Longee DC, Friedman HS, Albright RE, et al. Treatment of patients with recurrent gliomas with cyclophosphamide and vincristine. J Neurosurg. 1990;72:583-588.
18. Crist WM, Ragab AH, Vietti TJ, et al. Chemotherapy of childhood medulloblastoma. Am J Dis Child. 1976;13:639-642.
19. Friedman HS, Mahaley MS, Schold SC, et al. Efficacy of vincristine and cyclophosphamide in the therapy of recurrent medulloblastoma. Neurosurgery. 1986;18:335-340.
20. Kellie SJ, Uges DR, Koopmans P, et al. Pitfalls of long-distance pharmacokinetics: implications for collaborative chemotherapy studies. Med Pediatr Oncol. 2002;38:369-370.
21. Bloemhof H, Van Dijk KN, de Graaf SS, et al. Sensitive method for the determination of vincristine in human serum by high-performance liquid chromatography after online column-extraction. J Chromatogr. 1991;572:171-179.
22. D'Argenio DZ, Schumitzky A. ADAPT II user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Los Angeles: Biomedical Simulations Resource, 1997.
23. Scheithauer W, Ludwig H, Maida E. Acute encephalopathy associated with continuous vincristine sulphate combination therapy: case report. Invest New Drugs. 1985;3:315-318.
24. Whittaker JA, Parry DH, Bunch C, Weatherall DJ. Coma associated with vincristine therapy. Br Med J. 1973;4:335-337.
25. Kaufman IA, Kung FH, Koenig HM, Giannona ST. Overdosage with vincristine. J Pediatr. 1976;89:671-674.
26. Darnell J, Lodish H, Baltimore D. Molecular cell biology. New York: Scientific American Books, 1986.
27. Jordan MA, Thrower D, Wilson L. Mechanism of inhibition of cell proliferation by vinca alkaloids. Cancer Res. 1991;51: 2212-2222.
28. Pittman SM, Strickland D, Ireland CM. Polymerization of tubulin in apoptotic cells is not cell cycle dependent. Exp Cell Res. 1994;215:263-272.
29. Hill SA, Lonergan SJ, Denekamp J, Chaplin DJ. Vinca alkaloids: anti-vascular effects in a murine tumour. Eur J Cancer. 1993;29A:1320-1324.
30. Groninger E, de Graaf SS, Meeuwsen-de Boer GJ, et al. Vincristine-induced apoptosis in vivo in peripheral blood mononuclear cells with acute lymphoblastic leukaemia. Br J Haematol. 2000;111:875-878.
31. Jackson DV, Bender RA. Cytotoxic thresholds of vincristine in a murine and human leukemia cell line in vitro. Cancer Res. 1976;36:1499-1502.
32. Pinkerton CR, McDermott B, Philip T, et al. Continuous vincristine infusion as part of a high dose chemoradiotherapy regimen: drug kinetics and toxicity. Cancer Chemother Pharmacol. 1988;22:271-274.
33. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med. 1984;310:1353-1356.
34. Colleselli P, Dini G, Andolina M, et al. Autologous bone marrow transplantation for acute lymphoblastic leukemia: the high dose vincristine study of AIEOP BMT Group. Bone Marrow Transplant. 1991;7 Suppl 3:28-30.
35. Jackson DV, Case LD, Pope EK, et al. Single agent vincristine by infusion in refractory multiple myeloma. J Clin Oncol. 1985;3:1508-1512.
36. Schabel FM Jr., Griswold DP Jr., Corbett TH, Laster WR Jr. Increasing the therapeutic response rates of anticancer drugs by applying the basic principles of pharmacology. Cancer. 1984;54:1160-1167.
37. Pinkel D, Hernandez K, Borella L, et al. Drug dosage and remission duration in childhood lymphocytic leukemia. Cancer. 1971;27:247-256.
38. Jackson DV Jr., Sethi VS, Spurr CL, et al. Intravenous vincristine infusion: a Phase I trial. Cancer. 1981;48:2559-2564.
39. Bleyer WA, Frisby SA, Oliverio VT. Uptake and binding of vincristine by murine leukemia cells. Biochem Pharmacol. 1975;24:633-639.
40. Houghton JA, Torrance PM, Houghton PJ. Chromatographic analysis of vinca alkaloids in human neoplastic tissues and host (mouse) tissues after injection in vivo or after incubation in vitro. Anal Biochem. 1983;134:450-454.
41. Horton JK, Houghton PJ, Houghton JA. Relationships between tumor responsiveness, vincristine pharmacokinetics and arrest of mitosis in human tumor xenografts. Biochem Pharmacol. 1988;37:3995-4000.
42. Groninger E, Meeuwsen-de Boer T, Koopmans P, et al. Pharmacokinetics of vincristine monotherapy in childhood acute lymphoblastic leukemia. Pediatr Res. 2002;52:113-118.